Sutro BIOPHARMA, Inc. (STRO) intrinsic value & 10-year financials
Sutro BIOPHARMA, Inc. (STRO) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 6.2% a year to $102.5M, with an average return on invested capital of 171.2%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $10.94
- Market cap
- $93.0M
- Revenue (FY2025)
- $102.5M
- Revenue growth (10-yr CAGR)
- 6.2%
- ROIC (10-yr avg)
- 171.2%
- Free cash flow (FY2025)
- —
STRO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $102.5M | -$191.1M | -$22.49 | — | -154.5% | 101.2% |
| FY2024 | $62.0M | -$227.5M | -$2.96 | — | -384.3% | 2125.9% |
| FY2023 | $153.7M | -$106.8M | -$1.78 | — | -58.1% | -55.2% |
| FY2022 | $67.8M | -$119.2M | -$2.35 | — | -190.3% | -52.2% |
| FY2021 | $61.9M | -$105.5M | -$2.29 | — | -159.2% | -45.9% |
| FY2020 | $42.7M | -$32.1M | -$0.99 | — | -166.3% | -56.4% |
| FY2019 | $42.7M | -$55.7M | — | — | -129.8% | -94.1% |
| FY2018 | $38.4M | -$35.3M | — | $11.1M | -96.9% | -229.2% |
| FY2017 | $51.7M | -$19.7M | — | -$40.4M | -37.2% | 19.3% |
| FY2016 | $59.7M | $1.7M | — | -$17.5M | 2.3% | -1.9% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
SUTRO BIOPHARMA, INC. has demonstrated mature, steady growth, with revenue compounding at 6.2% annually over the past decade.
SUTRO BIOPHARMA, INC. has historically struggled to out-earn its cost of capital, averaging just -16.6% ROIC.
SUTRO BIOPHARMA, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, SUTRO BIOPHARMA, INC. is modeled at 6.2% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-404.75 per share.